Rationale: Endometrial cancer patients with lung metastases are rare, and more rarely with long-term management of progesterone after recurrence.
Patient concerns: Informed consent of the patients and their families.
Diagnoses: Endometrial cancer (IVB) (Refer to 2009 FIGO stag of endometrial cancer).
Interventions: the patient was treated with Megestrol Acetate Dispersible Tablets (trade name Yilizhi), 160 mg, orally, once daily, without interruption.
Outcomes: The patient has been treated with progesterone therapy for stable conditions and her survival time is already roughly a decade (December 2006-October 2016).
Lessons: Hormone therapy may as a long-term management for hormone receptor-positive patients with recurrent endometrial cancer.
Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.